Flapless procedure corrects presbyopia

Article

Intrastromal treatment optimal for patients with mild hyperopia, has strict indications

Flapless intrastromal correction of presbyopia (IntraCor) with a femtosecond laser (Femtec 520F, Technolas Perfect Vision) provides good presbyopic correction with slight decreases in distance vision. However, the indications for the monovision procedure are strict and it provides the optimal results in patients with mild hyperopia.

Dr Erik L. Mertens, FEBOphth, presented his findings at the annual meeting of the American Society of Cataract and Refractive Surgery.

The technique

The femtosecond laser is an 80KHz device. When performing the presbyopia treatment, 40 KHz is used. Using this procedure, five microscopic, concentric ring patterns are created in the stroma that alter the corneal curvature and correct presbyopia. The creation of three and six rings is being investigated but is not yet approved. Currently, one eye is treated at a time, and the nondominant eye is treated first, explained Dr Mertens.

Immediately postoperatively, air bubbles are visible in the cornea and almost resolve by 2 hours after the procedure; by 1 month postoperatively the effects of the procedure are barely visible. Dr Mertens showed on optical coherence tomography images that there is a safety zone between Descemet's membrane and the area treated with the procedure.

Probably the most important aspect of this procedure is centration. Topographic evaluation shows central steepening that, according to Dr Mertens, works very well, when the treatment is well centred.

"With this procedure, centration is extremely important," he said.

In Dr Merten's hands, this procedure is best performed in patients who have refractive errors of +0.5 to +1.25 D. When he initially treated patients who had plano presbyopia, the patients were unhappy postoperatively with the slight myopic shift and resultant mild loss of their distance visual acuity. After the surgery, patients who had mild hyperopia had some glare and halos, and some patients developed dry eye, but these may not be related to the procedure.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.